kynurenine has been researched along with Osteoporosis in 9 studies
Kynurenine: A metabolite of the essential amino acid tryptophan metabolized via the tryptophan-kynurenine pathway.
kynurenine : A ketone that is alanine in which one of the methyl hydrogens is substituted by a 2-aminobenzoyl group.
Osteoporosis: Reduction of bone mass without alteration in the composition of bone, leading to fractures. Primary osteoporosis can be of two major types: postmenopausal osteoporosis (OSTEOPOROSIS, POSTMENOPAUSAL) and age-related or senile osteoporosis.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Kynurenines were analysed by HPLC." | 5.33 | Kynurenine pathway metabolism in patients with osteoporosis after 2 years of drug treatment. ( Darlington, LG; Forrest, CM; Mackay, GM; Oxford, L; Stone, TW; Stoy, N, 2006) |
| "Kynurenine analysis was performed by HPLC." | 5.32 | Kynurenine and neopterin levels in patients with rheumatoid arthritis and osteoporosis during drug treatment. ( Darlington, LG; Forrest, CM; Kennedy, A; Stone, TW; Stoy, N, 2003) |
| "Age-induced osteoporosis is a global problem." | 2.82 | Role of Essential Amino Acids in Age-Induced Bone Loss. ( Lv, Z; Shi, W; Zhang, Q, 2022) |
| "Osteoporosis is also associated with abnormalities of the kynurenine pathway, reflected in an inversion of the ratio between blood levels of the metabolites anthranilic acid and 3-hydroxy-anthranilic acid." | 2.66 | IDO activation, inflammation and musculoskeletal disease. ( Clanchy, FI; Huang, YS; Ogbechi, J; Stone, TW; Topping, LM; Williams, RO, 2020) |
| "Osteoporosis is an age-related deterioration in bone health that is, at least in part, a stem cell disease." | 1.56 | Kynurenine inhibits autophagy and promotes senescence in aged bone marrow mesenchymal stem cells through the aryl hydrocarbon receptor pathway. ( Aguilar-Perez, A; Barrett, T; Bragg, RT; Eisa, N; Elmansi, A; Fulzele, S; Hamrick, M; Hill, W; Isales, C; Kondrikov, D; Kondrikova, G; Lawrence, MM; Mobley, T; Schoeinlein, P; Shi, XM, 2020) |
| "Kynurenines were analysed by HPLC." | 1.33 | Kynurenine pathway metabolism in patients with osteoporosis after 2 years of drug treatment. ( Darlington, LG; Forrest, CM; Mackay, GM; Oxford, L; Stone, TW; Stoy, N, 2006) |
| "Kynurenine analysis was performed by HPLC." | 1.32 | Kynurenine and neopterin levels in patients with rheumatoid arthritis and osteoporosis during drug treatment. ( Darlington, LG; Forrest, CM; Kennedy, A; Stone, TW; Stoy, N, 2003) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (22.22) | 29.6817 |
| 2010's | 1 (11.11) | 24.3611 |
| 2020's | 6 (66.67) | 2.80 |
| Authors | Studies |
|---|---|
| Lv, Z | 1 |
| Shi, W | 1 |
| Zhang, Q | 1 |
| Ballesteros, J | 1 |
| Rivas, D | 1 |
| Duque, G | 2 |
| Kondrikov, D | 1 |
| Elmansi, A | 1 |
| Bragg, RT | 1 |
| Mobley, T | 1 |
| Barrett, T | 1 |
| Eisa, N | 1 |
| Kondrikova, G | 1 |
| Schoeinlein, P | 1 |
| Aguilar-Perez, A | 1 |
| Shi, XM | 1 |
| Fulzele, S | 2 |
| Lawrence, MM | 1 |
| Hamrick, M | 1 |
| Isales, C | 1 |
| Hill, W | 1 |
| Pierce, JL | 1 |
| Roberts, RL | 1 |
| Yu, K | 1 |
| Kendall, RK | 1 |
| Kaiser, H | 1 |
| Davis, C | 1 |
| Johnson, MH | 1 |
| Hill, WD | 2 |
| Isales, CM | 2 |
| Bollag, WB | 1 |
| Hamrick, MW | 2 |
| McGee-Lawrence, ME | 2 |
| Ogbechi, J | 1 |
| Clanchy, FI | 1 |
| Huang, YS | 1 |
| Topping, LM | 1 |
| Stone, TW | 3 |
| Williams, RO | 1 |
| Patel, D | 1 |
| Potter, M | 1 |
| Anaya, JM | 1 |
| Vidal, C | 1 |
| Li, W | 1 |
| Santner-Nanan, B | 1 |
| Lim, CK | 1 |
| Guillemin, GJ | 1 |
| Ball, HJ | 1 |
| Hunt, NH | 1 |
| Nanan, R | 1 |
| Forrest, CM | 2 |
| Kennedy, A | 1 |
| Stoy, N | 2 |
| Darlington, LG | 2 |
| Mackay, GM | 1 |
| Oxford, L | 1 |
4 reviews available for kynurenine and Osteoporosis
| Article | Year |
|---|---|
Role of Essential Amino Acids in Age-Induced Bone Loss.
Topics: Aged; Amino Acids, Essential; Bone Density; Cell Differentiation; Humans; Isoleucine; Kynurenine; Ly | 2022 |
The Role of the Kynurenine Pathway in the Pathophysiology of Frailty, Sarcopenia, and Osteoporosis.
Topics: Aged; Aged, 80 and over; Frailty; Humans; Kynurenine; Osteoporosis; Sarcopenia; Tryptophan | 2023 |
IDO activation, inflammation and musculoskeletal disease.
Topics: Animals; Arthritis, Rheumatoid; Female; Humans; Indoleamine-Pyrrole 2,3,-Dioxygenase; Inflammation; | 2020 |
Kynurenine induces an age-related phenotype in bone marrow stromal cells.
Topics: Autophagy; Bone Marrow Cells; Cellular Senescence; Humans; Kynurenine; Musculoskeletal Physiological | 2021 |
5 other studies available for kynurenine and Osteoporosis
| Article | Year |
|---|---|
Kynurenine inhibits autophagy and promotes senescence in aged bone marrow mesenchymal stem cells through the aryl hydrocarbon receptor pathway.
Topics: Animals; Autophagy; Basic Helix-Loop-Helix Transcription Factors; beta-Galactosidase; Bone Marrow Ce | 2020 |
Kynurenine suppresses osteoblastic cell energetics in vitro and osteoblast numbers in vivo.
Topics: Aging; Animals; Bone and Bones; Bone Density; Cell Differentiation; Female; Histone Deacetylases; Ky | 2020 |
The kynurenine pathway of tryptophan degradation is activated during osteoblastogenesis.
Topics: Animals; Cell Differentiation; Female; Humans; Kynurenine; Mesenchymal Stem Cells; Mice; Mice, Inbre | 2015 |
Kynurenine and neopterin levels in patients with rheumatoid arthritis and osteoporosis during drug treatment.
Topics: Arthritis, Rheumatoid; Case-Control Studies; Etidronic Acid; Female; Humans; Kynurenine; Methotrexat | 2003 |
Kynurenine pathway metabolism in patients with osteoporosis after 2 years of drug treatment.
Topics: 3-Hydroxyanthranilic Acid; Aged; Anti-Inflammatory Agents, Non-Steroidal; Female; Humans; Indomethac | 2006 |